Keyword: Eli Lilly

At the annual meeting of the American College of Cardiology this week, a new analysis of Merck’s anacetrapib cast a shadow on DalCor’s hypothesis

It’s a pretty good news day for NGM Bio: Merck doubled down on its R&D pact, and it’s nabbed a Genentech executive to help run its trials.

Boston startup Karuna Therapeutics has raised a chunky $68 million as it looks to beef up work on its Alzheimer’s/schizophrenia combo therapy.

The appointment reunites Christian Felder with xanomeline, a once-failed Alzheimer’s disease drug he helped through early development at Eli Lilly.

Two years after leading AnTolRx's $4 million series A, Pfizer is moving on an option to take over development of the upstart's lead candidate.

Eli Lilly and Pfizer’s nonopioid NGF inhibitor tanezumab beat out placebo in a phase 3 study of patients with chronic lower back pain.

The Big Pharma has culled a dual amylin calcitonin receptor agonist, a BTK inhibitor and a urocortin-2 peptide.

Aduro Biotech is throwing its resources behind assets that target the STING and APRIL pathways for the treatment of cancer.

Pfizer and Lilly now have two trials showing NGF blocker tanezumab reduces pain in arthritis, but cases of rapid joint damage are still seen.